More Neurotech News

Browse all of our neurotechnology articles over the years. Remember you can click on the tags or search for specific articles.

This shows blood samples.
Researchers have developed an innovative device that can diagnose glioblastoma, an aggressive brain cancer, in under an hour using a novel biochip. The chip leverages electrokinetic technology to detect active Epidermal Growth Factor Receptors (EGFRs) in extracellular vesicles from a small blood sample. This method offers high sensitivity and selectivity, minimizing interference and potentially improving early detection. The technology could be adapted for diagnosing other diseases, enhancing its clinical impact.
This shows the BMI chip.
Researchers developed a compact, low-power brain-machine interface (BMI) called MiBMI, designed to enhance communication for individuals with severe motor impairments. The device translates neural activity into text with 91% accuracy, using a highly miniaturized system that processes data in real-time. This innovation opens the door to practical, implantable BMIs, promising significant improvements in quality of life for patients with conditions like ALS and spinal cord injuries.
This shows a person in an EEG cap.
A century after the first human brainwave recording, EEG technology has revolutionized our understanding of brain function, particularly in diagnosing epilepsy. Experts now predict that within a generation, EEG could become a widespread tool for cognitive enhancement, early diagnosis, and communication for those with severe disabilities. However, ethical concerns about privacy and the commercialization of EEG data loom large as the technology advances.
This shows a brain and sound waves.
A new study finds that 40Hz light and sound therapy helps maintain myelin, a crucial brain structure, in Alzheimer's patients. This therapy, which protects neurons and supports brain function, could offer new treatment avenues for neurodegenerative diseases. Researchers discovered that this stimulation enhances neural connections and reduces harmful inflammation. The therapy also shows potential for treating other conditions involving myelin loss, such as multiple sclerosis.
This shows a brain.
Researchers genetically engineered the parasite Toxoplasma gondii to deliver drugs across the blood-brain barrier. This innovative approach has been used to deliver therapeutic proteins to neurons, showing promise for treating neurological conditions like Rett syndrome. The research highlights the potential for parasites to act as delivery vehicles for large molecules that typically struggle to penetrate the brain. This breakthrough could lead to new treatments for a variety of neurological disorders.
This shows a psychedelic brain.
Researchers developed a rapid, noninvasive tool called CaST that tracks neurons and biomolecules activated by psychedelic drugs. This new method allows researchers to observe the cellular processes responsible for the neuroplastic effects of psychedelics, offering insights into treatments for brain disorders like depression and PTSD.
This shows a woman and speech bubbles.
Researchers enabled a silent person to produce speech using thought alone. Depth electrodes in the participant's brain transmitted electrical signals to a computer, which then vocalized imagined syllables. This technology offers hope for paralyzed individuals to regain speech. The study marks a significant step towards brain-computer interfaces for voluntary communication.
This shows a model of a head and neurons.
Researchers discovered a neural activity pattern that can accurately predict and monitor the clinical status of OCD patients undergoing deep brain stimulation (DBS). The study highlights how this biomarker can guide DBS therapy, improving treatment outcomes for those with severe, treatment-resistant OCD.
This shows a depressed woman.
Researchers reveal how targeting transcranial magnetic stimulation (TMS) could enhance treatment for depression. The study identified an electrophysiological marker that could predict TMS efficacy and guide personalized therapy. By optimizing the stimulation site and coil angle, treatment outcomes may improve. These findings offer hope for better, tailored TMS therapies in the future.
This shows a brain.
A groundbreaking implantable device has significantly reduced the frequency and severity of seizures in children with severe epilepsy, according to a new UK clinical trial. The rechargeable device, attached to the skull, delivers constant electrical stimulation to the brain, allowing patients like Oran to experience dramatic improvements in quality of life. This trial, known as the CADET pilot, is the first to measure this treatment for pediatric epilepsy and shows promise for broader applications. Further research will expand to more patients, aiming for a new standard in epilepsy treatment.